The Block Firm secured two important wins in our case, Faulkner et al v. Acella Pharmaceuticals, on behalf of NP Thyroid patients. On Monday, July 10, the Court denied Acella’s attempts to limit the scope of the putative nationwide class in every respect and provided a firm roadmap for the upcoming class certification motion. Acella had asked the Court to strike Plaintiffs’ class definition and class allegation based on Plaintiffs seeking to represent a supposedly overbroad and “fail-safe” class. In a 24-page order, the Court rejected Acella’s arguments. As noted in this Law360 article, the Court went as far as to observe that certain parts of the defendants’ arguments were “a bit disingenuous,” clearing the way for class claims that potentially date back to 2010. Bloomberg also posted an article about this which you can read here . The next day, the Court rejected Acella’s attempts to hide damaging documents and ordered the company to produce information about its defective drugs. Our team at The Block Firm LLC looks forward to continuing to vigorously represent patients across the country who were injured by Acella’s fraudulent and unsafe conduct.
If you would like more information on The Block Firm’s case against Acella, please click here.
